BZPEERReading, trust and collaboration for research
Menu

Discover

GraphFollow connections around a paper, topic or saved view.

Workspaces

HomePick up where your research flow left off.InboxHandle requests, replies and notifications from one place.CollectionsCurate reading lists, evidence sets and shareable dossiers.ResearchSee your private provenance graph, trail and imports.CollaborationMove from discovery into focused discussion rooms.PublishDraft, preview and publish full-text research articles.

Network

ExpertsFind specialists worth following or asking for help.CommunitiesJoin research circles organized around shared work.PartnersSee external organizations active around the same topics.

Opportunities

ListingsBrowse roles, calls and collaborations with clearer fit signals.

Account

Log inReturn to your reading and collaboration workspace.Create accountStart saving work, following people and joining teams.
Log inCreate account

Researcher profile

Jaume Bacardit

Jaume Bacardit contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate
Machine LearningArtificial Intelligenceeess.SYq-fin.TRSystems and Control

Trust snapshot

Quick read

Trust 15 - UnverifiedVerification L1Unclaimed author
3works
0followers
5topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

3 published item(s)

preprint2022arXiv

Benchmark time series data sets for PyTorch -- the torchtime package

The development of models for Electronic Health Record data is an area of active research featuring a small number of public benchmark data sets. Researchers typically write custom data processing code but this hinders reproducibility and can introduce errors. The Python package torchtime provides reproducible implementations of commonly used PhysioNet and UEA & UCR time series classification repository data sets for PyTorch. Features are provided for working with irregularly sampled and partially observed time series of unequal length. It aims to simplify access to PhysioNet data and enable fair comparisons of models in this exciting area of research.

0 citations0 reviewsNo code linkedOpen access
preprint2022arXiv

Volume-Centred Range Bars: Novel Interpretable Representation of Financial Markets Designed for Machine Learning Applications

Financial markets are a source of non-stationary multidimensional time series which has been drawing attention for decades. Each financial instrument has its specific changing-over-time properties, making its analysis a complex task. Hence, improvement of understanding and development of more informative, generalisable market representations are essential for the successful operation in financial markets, including risk assessment, diversification, trading, and order execution. In this study, we propose a volume-price-based market representation for making financial time series more suitable for machine learning pipelines. We use a statistical approach for evaluating the representation. Through the research questions, we investigate, i) whether the proposed representation allows the more efficient design of machine learning models; ii) whether the proposed representation leads to increased performance over the price levels market pattern; iii) whether the proposed representation performs better on the liquid markets, and iv) whether SHAP feature interactions are reliable to be used in the considered setting. Our analysis shows that the proposed volume-based method allows successful classification of the financial time series patterns, and also leads to better classification performance than the price levels-based method, excelling specifically on more liquid financial instruments. Finally, we propose an approach for obtaining feature interactions directly from tree-based models and compare the outcomes to those of the SHAP method. This results in the significant similarity between the two methods, hence we claim that SHAP feature interactions are reliable to be used in the setting of financial markets.

0 citations0 reviewsNo code linkedOpen access
preprint2020arXiv

Multi-classifier prediction of knee osteoarthritis progression from incomplete imbalanced longitudinal data

Conventional inclusion criteria used in osteoarthritis clinical trials are not very effective in selecting patients who would benefit from a therapy being tested. Typically majority of selected patients show no or limited disease progression during a trial period. As a consequence, the effect of the tested treatment cannot be observed, and the efforts and resources invested in running the trial are not rewarded. This could be avoided, if selection criteria were more predictive of the future disease progression. In this article, we formulated the patient selection problem as a multi-class classification task, with classes based on clinically relevant measures of progression (over a time scale typical for clinical trials). Using data from two long-term knee osteoarthritis studies OAI and CHECK, we tested multiple algorithms and learning process configurations (including multi-classifier approaches, cost-sensitive learning, and feature selection), to identify the best performing machine learning models. We examined the behaviour of the best models, with respect to prediction errors and the impact of used features, to confirm their clinical relevance. We found that the model-based selection outperforms the conventional inclusion criteria, reducing by 20-25% the number of patients who show no progression. This result might lead to more efficient clinical trials.

0 citations0 reviewsNo code linkedOpen access